These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 23551096)

  • 1. Achieving cancer cell death with PI3K/mTOR-targeted therapies.
    Yea SS; Fruman DA
    Ann N Y Acad Sci; 2013 Mar; 1280(1):15-8. PubMed ID: 23551096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
    Alzahrani AS
    Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting the PI3K/Akt/mTOR pathway--beyond rapalogs.
    Markman B; Dienstmann R; Tabernero J
    Oncotarget; 2010 Nov; 1(7):530-543. PubMed ID: 21317449
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular alterations of PI3K/Akt/mTOR pathway: a therapeutic target in endometrial cancer.
    Pavlidou A; Vlahos NF
    ScientificWorldJournal; 2014; 2014():709736. PubMed ID: 24526917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.
    Ediriweera MK; Tennekoon KH; Samarakoon SR
    Semin Cancer Biol; 2019 Dec; 59():147-160. PubMed ID: 31128298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Picking the point of inhibition: a comparative review of PI3K/AKT/mTOR pathway inhibitors.
    Dienstmann R; Rodon J; Serra V; Tabernero J
    Mol Cancer Ther; 2014 May; 13(5):1021-31. PubMed ID: 24748656
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the PI3K-AKT-mTOR signaling network in cancer.
    Khan KH; Yap TA; Yan L; Cunningham D
    Chin J Cancer; 2013 May; 32(5):253-65. PubMed ID: 23642907
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
    Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
    Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer.
    Yu L; Wei J; Liu P
    Semin Cancer Biol; 2022 Oct; 85():69-94. PubMed ID: 34175443
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Current clinical regulation of PI3K/PTEN/Akt/mTOR signalling in treatment of human cancer.
    Lim HJ; Crowe P; Yang JL
    J Cancer Res Clin Oncol; 2015 Apr; 141(4):671-89. PubMed ID: 25146530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of mTOR Signaling as a Therapeutic Target in Cancer.
    Popova NV; Jücker M
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33572326
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PI3K/Akt/mTOR pathway inhibitors in cancer: a perspective on clinical progress.
    Wu P; Hu YZ
    Curr Med Chem; 2010; 17(35):4326-41. PubMed ID: 20939811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors.
    LoRusso PM
    J Clin Oncol; 2016 Nov; 34(31):3803-3815. PubMed ID: 27621407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PI3K/AKT/mTOR inhibitors for the management of triple-negative breast cancer.
    Altundag K
    Med Oncol; 2024 Oct; 41(11):279. PubMed ID: 39400749
    [No Abstract]   [Full Text] [Related]  

  • 15. PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer.
    Zhu K; Wu Y; He P; Fan Y; Zhong X; Zheng H; Luo T
    Cells; 2022 Aug; 11(16):. PubMed ID: 36010585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of PI3K/Akt/mTOR signaling by natural products.
    Huang S
    Anticancer Agents Med Chem; 2013 Sep; 13(7):967-70. PubMed ID: 23272914
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent development in targeting PI3K-Akt-mTOR signaling for anticancer therapeutic strategies.
    Qazi AK; Hussain A; Hamid A; Qurishi Y; Majeed R; Ahmad M; Najar RA; Bhat JA; Singh SK; Zargar MA; Ali S; Saxena AK
    Anticancer Agents Med Chem; 2013 Dec; 13(10):1552-64. PubMed ID: 23438828
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting PI3K Signaling in Combination Cancer Therapy.
    Pons-Tostivint E; Thibault B; Guillermet-Guibert J
    Trends Cancer; 2017 Jun; 3(6):454-469. PubMed ID: 28718419
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combating TKI resistance in CML by inhibiting the PI3K/Akt/mTOR pathway in combination with TKIs: a review.
    Singh P; Kumar V; Gupta SK; Kumari G; Verma M
    Med Oncol; 2021 Jan; 38(1):10. PubMed ID: 33452624
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
    Polivka J; Janku F
    Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.